Literature DB >> 10102050

Insulin-like growth factor binding proteins: a proposed superfamily.

V Hwa1, Y Oh, R G Rosenfeld.   

Abstract

The conventional concept is that the insulin-like growth factor binding proteins (IGFBPs) are cysteine-rich proteins, with conserved N- and C-domains, that are capable of binding insulin-like growth factors (IGFs) with high affinity. This dogma was recently challenged by the discovery of a group of cysteine-rich proteins that share important structural similarities with the IGFBPs, but have demonstrably lower affinity for IGFs. It is therefore proposed that these IGFBP-related proteins (IGFBP-rPs) and the IGFBPs constitute an IGFBP superfamily. We speculate that the IGFBP superfamily is derived from an ancestral gene/protein that was critically involved in the regulation of cell growth and was capable of binding IGF peptides. Over the course of evolution, some members (IGFBPs) evolved into high-affinity IGF binders and others (IGFBP-rPs) into low-affinity IGF binders, thereby conferring on the IGFBP superfamily the ability to influence cell growth by both IGF-dependent and IGF-independent means.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102050     DOI: 10.1111/j.1651-2227.1999.tb14349.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  16 in total

Review 1.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 2.  Emerging therapeutic opportunities for skeletal restoration.

Authors:  Masanobu Kawai; Ulrike I Mödder; Sundeep Khosla; Clifford J Rosen
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

3.  Phylogenetic analysis of the insulin-like growth factor binding protein (IGFBP) and IGFBP-related protein gene families.

Authors:  Buel D Rodgers; Eric H Roalson; Cullen Thompson
Journal:  Gen Comp Endocrinol       Date:  2007-04-27       Impact factor: 2.822

Review 4.  The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity.

Authors:  Anastassios Philippou; Maria Maridaki; Spiros Pneumaticos; Michael Koutsilieris
Journal:  Mol Med       Date:  2014-05-07       Impact factor: 6.354

5.  Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Authors:  Lusia Sepiashvili; Angela Hui; Vladimir Ignatchenko; Willa Shi; Susie Su; Wei Xu; Shao Hui Huang; Brian O'Sullivan; John Waldron; Jonathan C Irish; Bayardo Perez-Ordonez; Fei-Fei Liu; Thomas Kislinger
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

6.  Targeting angiogenesis in childhood sarcomas.

Authors:  Hemant K Bid; Peter J Houghton
Journal:  Sarcoma       Date:  2010-12-09

7.  CTGF (IGFBP-rP2) is specifically expressed in malignant lymphoblasts of patients with acute lymphoblastic leukaemia (ALL).

Authors:  P Vorwerk; H Wex; B Hohmann; Y Oh; R G Rosenfeld; U Mittler
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

8.  Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3.

Authors:  Yagna P R Jarajapu; Jun Cai; Yuanqing Yan; Sergio Li Calzi; Jennifer L Kielczewski; Ping Hu; Lynn C Shaw; Sue M Firth; Tailoi Chan-Ling; Michael E Boulton; Robert C Baxter; Maria B Grant
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

9.  IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer.

Authors:  Toshiki Hirakawa; Masakazu Yashiro; Akihiro Murata; Keiichiro Hirata; Kenjiro Kimura; Ryosuke Amano; Nobuya Yamada; Bunzo Nakata; Kosei Hirakawa
Journal:  BMC Cancer       Date:  2013-08-21       Impact factor: 4.430

10.  Downregulation of SPARC expression inhibits the invasion of human trophoblast cells in vitro.

Authors:  Yahong Jiang; Yan Zhu; Yan Shi; Yaping He; Zhichao Kuang; Zhaogui Sun; Jian Wang
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.